Consistent with our findings, ADA (2023) reported improved glycemic outcomes in individuals on insulin pump therapy [15]. While hypoglycemia was a major adverse effect of intensified insulin therapy in the Diabetes Control and Complications Trial (DCCT) [4], data suggest that insulin pumps may reduce the rates of severe hypoglycemia compared with MDI [15]. The gene discussed is INS; the disease is diabetes mellitus.